Jazz Pharmaceuticals To Acquire Actio Biosciences In $820M Deal

Jazz Pharmaceuticals plc (JAZZ) announced that it has entered into a definitive agreement to acquire privately held Actio Biosciences, Inc. for $820 million upfront and up to $500 million in contingent consideration.